by The global tuberculosis diagnostics market size was estimated to be around US$ 2.2 billion in 2022. It is projected to reach US$ 3.67 billion by 2032, indicating a CAGR of 5.3% from 2023 to 2032.
Key Takeaways
- Asia-Pacific contributed more than 39% of revenue share in 2022.
- North America is projected to grow at a notable CAGR of 8.1% during the forecast period.
- By Test Type, the diagnostic laboratory segment has held the major revenue share of 42% in 2022.
- By Test Type, the cytokine detection assay segment is anticipated to grow at a CAGR of 7.7% during the projected period.
- By End-use, the diagnostic laboratories segment accounted more than 48% of revenue share in 2022.
- By End-use, the hospitals and clinics segment is estimated to expand at the fastest CAGR over the projected period.
Tuberculosis Diagnostics Market Overview:
The Tuberculosis Diagnostics Market is a dynamic sector within the healthcare industry dedicated to the detection and monitoring of tuberculosis (TB), a bacterial infection that primarily affects the lungs. As TB remains a global health concern, the diagnostics market plays a crucial role in early identification, treatment initiation, and prevention of the spread of the disease. The market encompasses a range of diagnostic tools and techniques, including molecular tests, chest X-rays, and serological tests, contributing to a comprehensive approach to TB detection.
Get a Sample: https://www.precedenceresearch.com/sample/3420
Tuberculosis Diagnostics Market Scope
| Report Coverage | Details |
| Growth Rate from 2023 to 2032 | CAGR of 5.3% |
| Market Size in 2023 | USD 2.31 Billion |
| Market Size by 2032 | USD 3.67 Billion |
| Largest Market | Asia-Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Test Type and By End-use |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Osteoporosis Treatment Market Will be Worth Nearly $ 18.45 Billion By 2032
Growth Factors:
Several factors contribute to the growth of the Tuberculosis Diagnostics Market. First and foremost is the increasing prevalence of TB globally, driving the demand for accurate and efficient diagnostic tools. Additionally, technological advancements in diagnostic methods, such as the development of rapid molecular tests and automated systems, enhance the speed and accuracy of TB diagnosis. Growing awareness about the importance of early detection, coupled with government initiatives and funding for TB control programs, further fuel market growth. Furthermore, the integration of artificial intelligence and machine learning in diagnostic tools is poised to revolutionize TB diagnostics, offering more precise and efficient results.
Regions Snapshot :
The Tuberculosis Diagnostics Market exhibits a widespread presence across the globe, with a particular focus on regions where TB incidence is high. High-burden countries in Asia and Africa, including India, China, South Africa, and Nigeria, are significant contributors to the market’s growth. North America and Europe also play a crucial role, driven by advanced healthcare infrastructure, research and development activities, and increasing awareness. Moreover, the market is expanding in Latin America and the Middle East as efforts to combat TB gain momentum in these regions. The global nature of TB makes the Tuberculosis Diagnostics Market a vital component in the global health landscape, with a need for accessible and efficient diagnostic solutions across diverse geographic areas.
Reasons to Purchase this Report:
- Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
- In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
- Market size in USD million and volume in million units provided for each segment and sub-segment.
- Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
- Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.
Recent Developments
- In June 2023, QIAGEN underscored the distinctive merits of its proprietary TB blood testing technology, the QuantiFERON-TB Gold Plus test. This innovative interferon-gamma release assay (IGRA) empowers the detection of CD4 T-cell responses in TB1 blood collection tubes and CD8 T-cell responses in TB2 blood collection tubes, enhancing its diagnostic capabilities.
- In February 2023, QuantiFERON-TB Gold Plus had achieved CE-marking compliance with the European Union’s In Vitro Diagnostic Medical Devices Regulation (IVDR), affirming its adherence to stringent quality and safety standards.
- In February 2023, Thermo Fisher Scientific secured licensing rights from the Central Drugs Standard Control Organization (CDSCO) for the Applied Biosystems TaqPath PCR kits. These kits encompass various infectious diseases, including M. tuberculosis complex (MTB) and multi-drug-resistant tuberculosis (MTB MDR), bolstering Thermo Fisher’s offerings in the realm of infectious disease diagnostics.
Tuberculosis Diagnostics Market Players
- Abbott Laboratories
- Becton, Dickinson and Company
- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific Inc.
- BioMérieux SA
- Hain Lifescience GmbH
- QIAGEN GmbH
- Cepheid
- Hologic, Inc.
- BD
Market Segmentations
By Test Type
- Radiographic Method
- Diagnostic Laboratory Methods
- Nucleic Acid Testing
- Phage Assay
- Detection of Latent Infection (Skin Test & IGRA)
- Cytokine Detection Assay
- Detection of Drug Resistance (DST)
- Other Methods
By End-use
- Diagnostic Laboratories
- Hospitals & Clinics
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Tuberculosis Diagnostics Market
5.1. COVID-19 Landscape: Tuberculosis Diagnostics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Tuberculosis Diagnostics Market, By Test Type
8.1. Tuberculosis Diagnostics Market, by Test Type, 2023-2032
8.1.1. Radiographic Method
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Diagnostic Laboratory Methods
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Nucleic Acid Testing
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Phage Assay
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Detection of Latent Infection (Skin Test & IGRA)
8.1.5.1. Market Revenue and Forecast (2020-2032)
8.1.6. Cytokine Detection Assay
8.1.6.1. Market Revenue and Forecast (2020-2032)
8.1.7. Detection of Drug Resistance (DST)
8.1.7.1. Market Revenue and Forecast (2020-2032)
8.1.8. Other Methods
8.1.8.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Tuberculosis Diagnostics Market, By End-use
9.1. Tuberculosis Diagnostics Market, by End-use, 2023-2032
9.1.1. Diagnostic Laboratories
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Hospitals & Clinics
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Tuberculosis Diagnostics Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.1.2. Market Revenue and Forecast, by End-use (2020-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.1.3.2. Market Revenue and Forecast, by End-use (2020-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.1.4.2. Market Revenue and Forecast, by End-use (2020-2032)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.2.2. Market Revenue and Forecast, by End-use (2020-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.2.3.2. Market Revenue and Forecast, by End-use (2020-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.2.4.2. Market Revenue and Forecast, by End-use (2020-2032)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.2.5.2. Market Revenue and Forecast, by End-use (2020-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.2.6.2. Market Revenue and Forecast, by End-use (2020-2032)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.3.2. Market Revenue and Forecast, by End-use (2020-2032)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.3.3.2. Market Revenue and Forecast, by End-use (2020-2032)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.3.4.2. Market Revenue and Forecast, by End-use (2020-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.3.5.2. Market Revenue and Forecast, by End-use (2020-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.3.6.2. Market Revenue and Forecast, by End-use (2020-2032)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.4.2. Market Revenue and Forecast, by End-use (2020-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.4.3.2. Market Revenue and Forecast, by End-use (2020-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.4.4.2. Market Revenue and Forecast, by End-use (2020-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.4.5.2. Market Revenue and Forecast, by End-use (2020-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.4.6.2. Market Revenue and Forecast, by End-use (2020-2032)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.5.2. Market Revenue and Forecast, by End-use (2020-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.5.3.2. Market Revenue and Forecast, by End-use (2020-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Test Type (2020-2032)
10.5.4.2. Market Revenue and Forecast, by End-use (2020-2032)
Chapter 11. Company Profiles
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Becton, Dickinson and Company
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. F. Hoffmann-La Roche AG
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Thermo Fisher Scientific Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. BioMérieux SA
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Hain Lifescience GmbH
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. QIAGEN GmbH
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Cepheid
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Hologic, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. BD
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
